Fomite

63 ms·

901.
by Fomite 5y ago
The answer is a Phase IV clinical trial, which a number of vaccines have undergone post-approval and I suspect the COVID-19 vaccines will as well.
902.
by Fomite 5y ago
The...stunning mediocrity of VAERS data is in the "it is known" category, and has been since well before I started graduate school. It's important because it's useful for emergent self-reported issues, but there's a
903.
by Fomite 5y ago
We have very few (if any) species-specific pesticides or larvicides. We've been trying the "What if we just kill them outright?" approach to mosquito control (along with 'What if we can hide under nets', 'What
904.
by Fomite 5y ago
This is in contradiction to my experience working on medicine in Africa, where there are often very well trained people coping with a water system that doesn't always work.
905.
by Fomite 5y ago
"Move fast and break things" is less compelling when the things in question is someone's grandmother.
906.
by Fomite 5y ago
Similarly, in infection control and antimicrobial stewardship, at this point pitching Yet Another Decision Support Tool will get you dirty looks.
907.
by Fomite 5y ago
Or the VA, which is a massive single-payer healthcare system that would love to cut costs.
908.
by Fomite 5y ago
All over this thread, for one thing. Nate Silver and a number of other "data driven centrist" type commentators acting like there has been a massive shift in the weight of evidence. Dozens of "We're not saying this is tr
909.
by Fomite 5y ago
Ebola Reston did.
910.
by Fomite 5y ago
An alternative explanation is that the other COVID-19 narrative - that vaccines work, but those who are hesitant are essentially beyond convincing, and this is going to be both a long and boring years long slog to control globally and longe
911.
by Fomite 5y ago
That's not all that big of a grant. It's roughly twice the standard NIH R01. I can't imagine the head of NIAID being directly involved in that.
912.
by Fomite 5y ago
Meanwhile, elsewhere, people are arguing that COVID-19 can be studied in BSL-2 facilities: https://www.statnews.com/2020/04/14/allow-bsl-2-labs-handle-... There's a lot of post-hoc engineering arguing fo
913.
by Fomite 5y ago
Given it was posted May 31st, 2021 it's at best weeks away from completed peer review, and realistically with the timelines of COVID-19 papers these days, months.
914.
by Fomite 5y ago
I think the idea is to highlight this problem - especially as more and more labs have complex machinery with a PC as an essential component of it. And that this task is often not the responsibility of a research IT professional, but a puzzl
915.
by Fomite 5y ago
Weirdly, knowing this has helped me. My mind can imagine all kinds of horrific things happening with the sound and feeling of dental tools, so it's rather reassuring to be "Oh, yeah, that's what a glorified Dremel would sou
916.
by Fomite 5y ago
This is, indeed, often the point of commercial partnerships for universities - getting what you want to see out into the world. I don't remember the licensing terms for Catalyst specifically, but they are fairly aggressive, as far as
917.
by Fomite 5y ago
"As with any other disease, it is reasonable (and expected) for everyone who had covid to not get vaccinated, given that the immunity you get from having the disease is always better than what you'd get from a vaccine." This
918.
by Fomite 5y ago
I'm skeptical anyone has a decade long lead on anything in the consumer electronics space.
919.
by Fomite 5y ago
No, but it might have been better than what you had .
920.
by Fomite 5y ago
This. To use the NIH example, a new research institute is probably staring at some grim Environment scores for a bit.
921.
by Fomite 5y ago
Note that this isn't necessarily true. There are often two large differences between "Institutes" (or Centers, etc. - nomenclature differs from university to university): - Soft funding. Meaning very little to no support from
922.
by Fomite 5y ago
"In the US most research is targeted as selling things to the military." This strikes me as a very narrow perspective. Defense and Non-Defense R&D spending are about the same ( https://www.aaas.org/sites/de
923.
by Fomite 5y ago
I feel seen.
924.
by Fomite 5y ago
I will note I ended up at an institution (admittedly an academic one) that for my field is usually met with "Where?" because the funding allowed for some very nice quality of life considerations and more academic freedom/less
925.
by Fomite 5y ago
"In Canada, an Adjunct Professor is unpaid, but actually somewhat prestigious. It is a recognition of your abilities in a field and might be given to someone in industry who collaborates with a researcher at the university (for example
926.
by Fomite 5y ago
There is no "U.S. experience" because of the absolute mess of our healthcare system. There are birthing centers that work very much like the process described above.
927.
by Fomite 5y ago
I'd suggest the TIOBE index really isn't the proper metric to be using.
928.
by Fomite 5y ago
I'm just saying I have spent my entire career in "The year Python unseats R." and also "The year R unseats Python."
929.
by Fomite 5y ago
"R is very popular with stats people but new PhD candidates are beginning to write python implementations of R things (sort of how like DataFrames/pandas happened)." People have been saying this since I was an undergraduate.
930.
by Fomite 5y ago
I think it's somewhat more complex than that. I think tidyverse-R, which is a quasiseparate language, is only simple with complete buy in, and involves a lot of magic, shorthand, and "These are the symbols I put into the machine t

More ›